Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
22 10 2021
Historique:
received: 23 04 2021
accepted: 08 10 2021
entrez: 23 10 2021
pubmed: 24 10 2021
medline: 28 1 2022
Statut: epublish

Résumé

The anatomical location and extent of primary lung tumors have shown prognostic value for overall survival (OS). However, its manual assessment is prone to interobserver variability. This study aims to use data driven identification of image characteristics for OS in locally advanced non-small cell lung cancer (NSCLC) patients. Five stage IIIA/IIIB NSCLC patient cohorts were retrospectively collected. Patients were treated either with radiochemotherapy (RCT): RCT1* (n = 107), RCT2 (n = 95), RCT3 (n = 37) or with surgery combined with radiotherapy or chemotherapy: S1* (n = 135), S2 (n = 55). Based on a deformable image registration (MIM Vista, 6.9.2.), an in-house developed software transferred each primary tumor to the CT scan of a reference patient while maintaining the original tumor shape. A frequency-weighted cumulative status map was created for both exploratory cohorts (indicated with an asterisk), where the spatial extent of the tumor was uni-labeled with 2 years OS. For the exploratory cohorts, a permutation test with random assignment of patient status was performed to identify regions with statistically significant worse OS, referred to as decreased survival areas (DSA). The minimal Euclidean distance between primary tumor to DSA was extracted from the independent cohorts (negative distance in case of overlap). To account for the tumor volume, the distance was scaled with the radius of the volume-equivalent sphere. For the S1 cohort, DSA were located at the right main bronchus whereas for the RCT1 cohort they further extended in cranio-caudal direction. In the independent cohorts, the model based on distance to DSA achieved performance: AUC

Identifiants

pubmed: 34686719
doi: 10.1038/s41598-021-00239-0
pii: 10.1038/s41598-021-00239-0
pmc: PMC8536672
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

20890

Subventions

Organisme : Swiss National Science Foundation
ID : 310030_173303
Pays : Switzerland

Informations de copyright

© 2021. The Author(s).

Références

Ann Am Thorac Soc. 2017 Jan;14(1):118-123
pubmed: 27854541
J Thorac Cardiovasc Surg. 2006 Sep;132(3):544-8
pubmed: 16935108
Cancers (Basel). 2020 Jul 25;12(8):
pubmed: 32722386
World J Clin Oncol. 2017 Feb 10;8(1):1-20
pubmed: 28246582
Ann Thorac Surg. 2010 Apr;89(4):1053-9
pubmed: 20338306
Eur J Cardiothorac Surg. 2018 Jul 1;54(1):134-140
pubmed: 29447330
Thorac Cancer. 2018 Dec;9(12):1614-1622
pubmed: 30259691
Neuro Oncol. 2016 May;18(5):716-24
pubmed: 26519739
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Acta Oncol. 2019 Oct;58(10):1393-1398
pubmed: 31271075
Radiology. 2013 May;267(2):619-26
pubmed: 23329658
Mol Clin Oncol. 2015 May;3(3):706-712
pubmed: 26137291
Eur J Cardiothorac Surg. 2018 Feb 1;53(2):359-365
pubmed: 29029062
J Surg Res. 2012 Oct;177(2):185-90
pubmed: 22921916
J Digit Imaging. 2013 Dec;26(6):1045-57
pubmed: 23884657
J Thorac Cardiovasc Surg. 2001 Oct;122(4):803-8
pubmed: 11581617
Radiother Oncol. 2019 Feb;131:120-126
pubmed: 30773178
Med Phys. 2020 Sep;47(9):4045-4053
pubmed: 32395833
Lancet. 2015 Sep 12;386(9998):1049-56
pubmed: 26275735
Radiat Oncol. 2013 Dec 23;8:293
pubmed: 24365155
Eur J Cancer. 2017 Nov;85:106-113
pubmed: 28898766
Sci Rep. 2020 Sep 10;10(1):14933
pubmed: 32913267
J Neurooncol. 2020 Mar;147(1):229-235
pubmed: 32065345
Jpn J Clin Oncol. 1996 Aug;26(4):221-8
pubmed: 8765179
Radiat Oncol. 2015 Feb 07;10:35
pubmed: 25886315
Radiother Oncol. 2019 Aug;137:71-76
pubmed: 31078940

Auteurs

Diem Vuong (D)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. diem.vuong@usz.ch.

Marta Bogowicz (M)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Leonard Wee (L)

Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.

Oliver Riesterer (O)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Center for Radiation-Oncology, KSA-KSB, Kantonsspital Aarau AG, Aarau, Switzerland.

Eugenia Vlaskou Badra (E)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Louisa Abigail D'Cruz (LA)

Strahlentherapie und Onkologie, Universitätsklinikum Frankfurt, Frankfurt, Germany.

Panagiotis Balermpas (P)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Janita E van Timmeren (JE)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Simon Burgermeister (S)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

André Dekker (A)

Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.

Dirk De Ruysscher (D)

Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.

Jan Unkelbach (J)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Sandra Thierstein (S)

Swiss Group for Clinical Cancer Research (SAKK), Coordinating Center, Bern, Switzerland.

Eric I Eboulet (EI)

Swiss Group for Clinical Cancer Research (SAKK), Coordinating Center, Bern, Switzerland.

Solange Peters (S)

Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Miklos Pless (M)

Department of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.

Matthias Guckenberger (M)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Stephanie Tanadini-Lang (S)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH